article Open AccessTop 10% cited
Population-Based Study of Islet Cell Carcinoma
Annals of Surgical Oncology · 2007 · Vol. 14(12) · pp. 3492–3500
James C. Yao✉(The University of Texas MD Anderson Cancer Center)Milton P. Eisner(National Cancer Institute)Colleen Leary(The University of Texas MD Anderson Cancer Center)Cecile G. Dagohoy(The University of Texas MD Anderson Cancer Center)Alexandria T. Phan(The University of Texas MD Anderson Cancer Center)Asif Rashid(The University of Texas MD Anderson Cancer Center)Manal M. Hassan(The University of Texas MD Anderson Cancer Center)Douglas B. Evans(The University of Texas MD Anderson Cancer Center)
Abstract
Islet cell carcinomas account for approximately 1.3% of cancers arising in the pancreas. Most patients have advanced disease at the time of diagnosis. Despite the disease's reputation of being indolent, survival of patients with advanced disease remains only 2 years. Development of novel therapeutic approaches is needed.
Neuroendocrine Tumor Research AdvancesPancreatic and Hepatic Oncology ResearchLung Cancer Research StudiesMedicineEpidemiologyInternal medicineStage (stratigraphy)PopulationOncologySurveillance, Epidemiology, and End ResultsIncidence (geometry)Surgical oncologyCarcinoma
MeSH terms
AdolescentAdultAgedAged, 80 and overChildChild, PreschoolVipomaFemaleGlucagonomaHumansInfantInfant, NewbornInsulinomaMaleMiddle Aged
Funding
- Stuart Foundation
- Carcinoid Cancer Foundation
Citations
338
FWCI
7.05
field-weighted impact
References
18
Percentile
97%
vs. same field & year
Citations per year
Cited by
One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
Journal of Clinical Oncology · 2008 · 4,490 citations
References
A 5‐decade analysis of 13,715 carcinoid tumors
Cancer · 2003 · 2,734 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.